financetom
Business
financetom
/
Business
/
US Senate Democrats demand Kennedy explain canceling bird flu vaccine contract
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US Senate Democrats demand Kennedy explain canceling bird flu vaccine contract
Jun 18, 2025 5:34 AM

WASHINGTON, June 18 (Reuters) - U.S. Senate Democrats

demanded on Wednesday Health Secretary Robert F. Kennedy Jr.

make public the reviews on which his department said it based

its decision to cancel a contract for developing a bird flu

vaccine.

President Donald Trump's administration last month canceled

a $590-million contract awarded to Moderna ( MRNA ) in January

by outgoing President Joe Biden's administration for the

late-stage development of its bird flu vaccine for humans, as

well as the right to purchase shots.

"This is a grievous mistake that threatens to leave the

country unprepared for what experts fear might be the next

pandemic - and there appears to be no rationale for this

decision other than your ill-informed and dangerous war on

vaccines," Senators Elizabeth Warren and Tammy Duckworth wrote

in a letter seen by Reuters.

The cancellation endangers American lives and will likely

contribute to a 20% rise in the price of eggs this year, they

wrote to Kennedy, who has a long history of questioning the

safety of vaccines contrary to scientific evidence.

A spokesperson for the Department of Health and Human

Services at the time said the contract was canceled after a

comprehensive internal review determined the project did not

meet the scientific standards or safety expectations required

for continued federal investment.

Warren and Duckworth demanded Kennedy make the review

public, alongside a similar review the department cited when it

cut funding of a $258-million program researching an HIV

vaccine. They also asked for a detailed description of how the

department decided to end the contracts, and a staff briefing.

"You have failed to justify either of these moves to cripple

vaccine research," Warren and Duckworth wrote. "Furthermore,

these decisions appear to be part of your larger, unfounded

vendetta against mRNA technology."

Kennedy named eight members last week to serve on a panel of

vaccine advisers to the U.S. Centers for Disease Control and

Prevention, including some who have advocated against vaccines,

days after abruptly firing all 17 members who had been serving

on the independent committee of experts.

Several of his appointees specifically oppose the mRNA

vaccine technology used in some of the newest immunizations such

as the COVID-19 vaccine, including by Moderna ( MRNA ).

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US court upholds EPA decision to approve California electric vehicle rules
US court upholds EPA decision to approve California electric vehicle rules
Apr 9, 2024
WASHINGTON (Reuters) - A U.S. appeals court on Tuesday upheld the Environmental Protection Agency's decision to grant California a waiver to set its own tailpipe emissions limits and electric vehicle requirements. The three-judge panel of the U.S. Court of Appeals for the District of Columbia rejected a legal challenge from 17 Republican-led states and entities that sell or produce liquid...
Novartis to cut 680 jobs in product development
Novartis to cut 680 jobs in product development
Apr 9, 2024
ZURICH (Reuters) - Novartis is to cut up to 680 jobs in its development organisation, which helps bring its drugs to market, the Swiss pharmaceuticals company said on Tuesday. Around 440 jobs will go in Switzerland and up to 240 in the United States over the next two to three years, the Basel-based company said. The job eliminations are separate...
Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
Apr 9, 2024
On Monday, Vincerx Pharma Inc ( VINC ) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024. VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options.  Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule:...
Xencor Names Bart Cornelissen as Chief Financial Officer
Xencor Names Bart Cornelissen as Chief Financial Officer
Apr 9, 2024
10:27 AM EDT, 04/09/2024 (MT Newswires) -- Xencor ( XNCR ) said Tuesday it has appointed Bart Cornelissen as chief financial officer. Cornelissen most recently served as vice president of corporate finance at Seagen. Xencor ( XNCR ) shares were up 2.7% in recent trading. Price: 22.08, Change: +0.58, Percent Change: +2.67 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved